Collaboration will comprehensively profile
DNA, RNA and proteins on patient samples from the Phase 2 Maverick
trial to understand mechanisms of disease response and
resistance
IRVING,
Texas and SAN DIEGO,
June 2,
2022 /PRNewswire/ -- Caris Life
Sciences®(Caris), the leading molecular science and technology
company actively developing and delivering innovative solutions to
revolutionize healthcare, the Prostate Cancer Clinical Trial
Consortium (PCCTC) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE),
a clinical and commercial stage biopharmaceutical company
developing new therapies to treat cancer, pain (non-opioid
treatments), autoimmune disease and COVID-19, today announced a
strategic collaboration to guide more precise treatment decisions
for patients with advanced prostate cancer.
"The vast majority of men with prostate cancer do not have their
tumors molecularly profiled, in part because of the limited
targeted therapy options available for this disease," said
Brian Lamon, Ph.D., Chief Business
Officer at Caris Life Sciences. "We are very pleased to partner
with the PCCTC to leverage our industry-leading precision medicine
technologies and maximize the potential of molecular learnings from
Sorrento's Maverick trial to positively impact the future of cancer
treatments and drive better outcomes for patients with prostate
cancer."
The PCCTC was formed to address critically unmet needs in
prostate cancer, with a mission to design, implement and complete
early-phase process driven clinical trials and translate scientific
discoveries to improved standards of care. The Phase 2 Maverick
trial
(ClinicalTrials.gov Identifier: NCT05361915) is sponsored by
Sorrento and managed by the PCCTC. Utilizing Caris' unique MI
Profile, PCCTC investigators will profile whole exome DNA, whole
transcriptome RNA, and proteins from samples collected from
participants enrolled in the trial, creating a molecular blueprint
to better understand mechanisms of response and resistance
following therapy.
Maverick investigator Rana R. McKay, M.D.
of the University of California San
Diego (UCSD) noted, "This study is the first biomarker
clinical trial for patients with the HSD3B1 adrenal-permissive
genotype in men with metastatic castration resistant prostate. A
growing wave of data demonstrates that such patients exhibit
resistance to hormonal treatment. This study tests the efficacy and
safety of avibertinib plus abiraterone in this vulnerable patient
population." UCSD is one of 67 member sites of the Caris Precision
Oncology Alliance™, a growing network of leading cancer centers
across the globe that collaborate to advance precision oncology and
biomarker-driven research.
"We are excited to partner with Caris and utilize their next
generation sequencing platform and data analytics capabilities to
evaluate treatment response and resistance patterns in this study,"
added Jake Vinson, Chief Executive
Officer at the PCCTC. "Through this collaboration, we hope to gain
knowledge to better guide treatment options for future clinical
trial participants, and ultimately all patients with prostate
cancer."
Since the launch of its molecular profiling service in 2009,
Caris has amassed molecular data on more than 378,000
patients and real-world clinical outcomes on more than 275,000
patients. Caris has the most advanced sequencing laboratories in
the world, which allows the company to perform whole exome DNA
sequencing and whole transcriptome RNA sequencing on every patient.
Caris' data-driven, molecular insights are changing the landscape
of precision medicine with actionable insights from retrospective,
epidemiologic and real-time molecular data to enhance research and
commercial activities.
About Caris Life Sciences
Caris Life
Sciences® (Caris) is the leading molecular science
and technology company actively developing and delivering
innovative solutions to revolutionize healthcare and improve
patient outcomes. Through comprehensive molecular profiling (Whole
Exome and Whole Transcriptome Sequencing) and the application of
advanced artificial intelligence (AI) and machine learning
algorithms, Caris has created the large-scale clinico-genomic
database and cognitive computing needed to analyze and unravel the
molecular complexity of disease. This information provides an
unmatched resource and the ideal path forward to conduct the basic,
fundamental research to accelerate discovery for detection,
diagnosis, monitoring, therapy selection and drug development to
improve the human condition.
With a primary focus on cancer, Caris' suite of market-leading
molecular profiling offerings assesses DNA, RNA and proteins to
reveal a molecular blueprint that helps patients, physicians and
researchers better detect, diagnose and treat patients. Caris'
latest advancement, which is currently available within its
Precision Oncology Alliance, is a blood-based, circulating nucleic
acids sequencing (cNAS) assay that combines comprehensive molecular
analysis (Whole Exome and Whole Transcriptome Sequencing from
blood) and serial monitoring – making it the most powerful liquid
biopsy assay ever developed.
Headquartered in Irving, Texas,
Caris has offices in Phoenix, New
York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services
throughout the U.S., Europe,
Asia and other international
markets. To learn more, please
visit CarisLifeSciences.com or follow us on Twitter
(@CarisLS).
About The Prostate Cancer Clinical Trial
Consortium
The Prostate Cancer Clinical Trials Consortium
(PCCTC) was initiated in 2005 by the Prostate Cancer Foundation
(PCF) and the U.S. Department of Defense (DOD) Prostate Cancer
Research Program (PCRP) in response to critically unmet needs in
prostate cancer clinical research identified by physician
investigators and patient advocates. To fulfill their mission, the
PCCTC developed a unique infrastructure which has fostered a
culture of transparent project co-development between
investigators, research sites and industry partners. Established as
an independent entity in 2014, the PCCTC, LLC is now the nation's
premier multicenter clinical research organization specializing in
cutting-edge prostate cancer research. Through the collaborative
nature and intellectual synergy of its leadership, the PCCTC
remains poised to make a significant impact on the lives of
patients by keeping the pipeline primed with the most promising
novel agents and validated biomarkers. For more information, visit
www.pcctc.org.
About Sorrento Therapeutics, Inc.
Sorrento is a
clinical and commercial stage biopharmaceutical company developing
new therapies to treat cancer, pain (non-opioid treatments),
autoimmune disease and COVID-19. Sorrento's multimodal,
multipronged approach to fighting cancer is made possible by its
extensive immuno-oncology platforms, including key assets such as
fully human antibodies ("G-MAB™ library"), immuno-cellular
therapies ("DAR-T™"), antibody-drug conjugates ("ADCs"), and
oncolytic virus ("Seprehvec™"). Sorrento is also developing
potential antiviral therapies and vaccines against coronaviruses,
including Abivertinib, COVISHIELD™, and COVI-MSC™; and diagnostic
test solutions, including COVIMARK™.
Sorrento's commitment to life-enhancing therapies for patients
is also demonstrated by our effort to advance a first-in-class
(TRPV1 agonist) non-opioid pain management small molecule,
resiniferatoxin ("RTX"), and SP-102 (10 mg, dexamethasone sodium
phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation
of a widely used corticosteroid for epidural injections to treat
lumbosacral radicular pain, or sciatica, and to commercialize
ZTlido® (lidocaine topical system) 1.8% for the treatment of
post-herpetic neuralgia (PHN). RTX has been cleared for a Phase II
trial for intractable pain associated with cancer and a Phase II
trial in osteoarthritis patients. Positive final results from the
Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel,
non-opioid product for the treatment of lumbosacral radicular pain
(sciatica), were announced in March
2022. ZTlido® was approved by the FDA on February 28, 2018.
For more information, visit www.sorrentotherapeutics.com.
Forward-Looking Statements
This press release and any
statements made for and during any presentation or meeting contain
forward-looking statements related to Sorrento Therapeutics, Inc.,
under the safe harbor provisions of Section 21E of the Private
Securities Litigation Reform Act of 1995 and subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. Forward-looking statements include statements
regarding the strategic collaboration and its potential ability to
guide more precise treatment decisions and options for patients
with prostate cancer, as well as statements regarding Sorrento's
Phase 2 Maverick trial. Risks and uncertainties that could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements, include, but are not
limited to: risks related to Sorrento's technologies and prospects,
including, but not limited to risks related to safety and efficacy
for Sorrento's product candidates, including Abivertinib; clinical
development risks, including risks in the progress, timing, cost,
and results of clinical trials and product development programs;
risk of difficulties or delays in obtaining regulatory approvals;
risks that clinical study results may not meet any or all endpoints
of a clinical study and that any data generated from such studies
may not support a regulatory submission or approval; risks that
prior test, study and trial results may not be replicated in
continuing or future studies and trials; risks of manufacturing and
supplying drug product; risks related to leveraging the expertise
of its employees, subsidiaries, affiliates and partners to assist
Sorrento in the execution of its product candidates' strategies;
risks related to the global impact of COVID-19; and other risks
that are described in Sorrento's most recent periodic reports filed
with the Securities and Exchange Commission, including Sorrento's
Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission,
including the risk factors set forth in those filings. Investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release, and we
undertake no obligation to update any forward-looking statement in
this press release except as required by law.
Caris Life Sciences Media Contact:
Lisa Burgner
lburgner@carisls.com
(469) 822-9330
Caris Life Sciences Business Development
Contact:
Brian Lamon,
Ph.D.
Chief Business Officer, Head of BioPharma Business
Development
blamon@carisls.com
(609) 955-8883
Prostate Cancer Clinical Trial Cancer Consortium
Contact:
Kristofer Prepelica,
Ph.D.
Medical Communications Manager
prepelik@mskcc.org
Sorrento Therapeutics Contact
Brian Cooley
mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of
Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVISHIELD™, COVIDROPS™,
COVI-MSC™, COVIMARK™ and Fujovee™ are trademarks of Sorrento
Therapeutics, Inc.
SEMDEXA™ (SP-102) is a trademark of Semnur Pharmaceuticals, Inc.
A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex
Pharmaceuticals Inc.
All other trademarks are the property of their respective
owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-prostate-cancer-clinical-trial-consortium-and-sorrento-therapeutics-announce-collaboration-to-advance-precision-medicine-development-using-comprehensive-genomic-profiling-301559670.html
SOURCE Caris Life Sciences